Core Viewpoint - WuXi Biologics Holdings Limited plans to sell 150 million shares of WuXi Biologics at a price of HKD 38.52 per share, which represents approximately 3.63% of the company's total issued share capital as of the announcement date [1] Group 1 - The share placement agreement was made with Morgan Stanley as the placement agent [1] - Before the placement, Biologics Holdings held approximately 501 million shares, accounting for about 12.12% of the company's total issued share capital [1] - Following the completion of the placement, Biologics Holdings' ownership in the company will decrease to approximately 8.49%, and it will no longer be considered a major shareholder [1] Group 2 - The chairman and non-executive director, Li Ge, controls approximately 19.66% of Biologics Holdings' issued share capital and 55.03% of the voting rights at Biologics Holdings' shareholders' meeting [1]
药明生物(02269.HK)：主要股东Biologics Holdings拟配售1.5亿股现有股份